NO more muscle fatigue

Journal of Clinical Investigation

Volumn 119, Issue 3, 2009, Pages 448-450

  Heydemann, Ahlke ^a   McNally, Elizabeth ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSFERLIN; DYSTROPHIN; NEURONAL NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SPECTRIN; NITRIC OXIDE;

BECKER MUSCULAR DYSTROPHY; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; GENE REPLACEMENT THERAPY; HUMAN; MUSCLE CONTRACTION; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE FIBER MEMBRANE; MUSCULAR DYSTROPHY; NONHUMAN; NOTE; PRIORITY JOURNAL; SARCOLEMMA; VASCULARIZATION; VASODILATATION; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MUSCULAR DYSTROPHY; DISEASE MODEL; ENZYMOLOGY; FATIGUE; GENETICS; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; FATIGUE; MICE; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; PHYSICAL CONDITIONING, ANIMAL;

EID: 65649112428     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI38618     Document Type: Note

References (21)

1. Lapidos, K.A., Kakkar, R., and McNally, E.M. 2004. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ. Res. 94:1023-1031.
2. Brenman, J.E., Chao, D.S., Xia, H., Aldape, K., and Bredt, D.S. 1995. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 82:743-752.
3. Ahn, A.H., et al. 1996. The three human syntrophin genes are expressed in diverse tissues, have distinct chromosomal locations, and each bind to dystrophin and its relatives. J. Biol. Chem. 271:2724-2730.
4. Sander, M., et al. 2000. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 97:13818-13823.
5. Thomas, G.D., et al. 1998. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc. Natl. Acad. Sci. U. S. A. 95:15090-15095.
6. Chao, D.S., Silvagno, F., and Bredt, D.S. 1998. Muscular dystrophy in mdx mice despite lack of neuronal nitric oxide synthase. J. Neurochem. 71:784-789.
7. Crosbie, R.H., et al. 1998. mdx muscle pathology is independent of nNOS perturbation. Hum. Mol. Genet. 7:823-829.
8. Percival, J.M., Anderson, K.N., Gregorevic, P., Chamberlain, J.S., and Froehner, S.C. 2008. Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. PLoS ONE. 3:e3387.
9. Thomas, G.D., Shaul, P.W., Yuhanna, I.S., Froehner, S.C., and Adams, M.E. 2003. Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. Circ. Res. 92:554-560.
10. Phillips, B.A., and Mastaglia, F.L. 2000. Exercise therapy in patients with myopathy. Curr. Opin. Neurol. 13:547-552.
11. Duan, D. 2006. Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum. Mol. Genet. 15:R253-R261.
12. Kapsa, R., Kornberg, A.J., and Byrne, E. 2003. Novel therapies for Duchenne muscular dystrophy. Lancet Neurol. 2:299-310.
13. Banks, G.B., Gregorevic, P., Allen, J.M., Finn, E.E., and Chamberlain, J.S. 2007. Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Hum. Mol. Genet. 16:2105-2113.
14. Lai, Y., et al. 2009. Dystrophins carrying spectrinlike repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119:624-635.
15. Brenman, J.E., et al. 1996. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell. 84:757-767.
16. Kobayashi, Y.M., et al. 2008. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature. 456:511-515.
17. Khairallah, M., et al. 2008. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc. Natl. Acad. Sci. U. S. A. 105:7028-7033.
18. Cox, G.A., et al. 1993. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature. 364:725-729.
19. Petrof, B.J., Shrager, J.B., Stedman, H.H., Kelly, A.M., and Sweeney, H.L. 1993. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. U. S. A. 90:3710-3714.
20. Blaauw, B., et al. 2008. Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle. Hum. Mol. Genet. 17:3686-3696.
21. Grady, R.M., et al. 1999. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat. Cell. Biol. 1:215-220.